Evidence map›Paper›PMID 40038149›Full record

ReviewMolecular and cellular biochemistry2025

Chloride channels and mast cell function: pioneering new frontiers in IBD therapy.

Ahmed M Aljameeli, Bader Alsuwayt, Deepak Bharati, Vaishnavi Gohri, Popat Mohite, Sudarshan Singh, Vijay Chidrawar

Expression of concernAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Angiogenesis in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ahmed M AljameeliDepartment of Pharmacy Practice, College of Pharmacy, University of Hafr Al-Batin, Hafr Albatin, Saudi Arabia.
Bader AlsuwaytDepartment of Pharmacy Practice, College of Pharmacy, University of Hafr Al-Batin, Hafr Albatin, Saudi Arabia.
Deepak BharatiAETs St. John Institute of Pharmacy and Research, Palghar, Maharashtra, 401 404, India.
Vaishnavi GohriAETs St. John Institute of Pharmacy and Research, Palghar, Maharashtra, 401 404, India.
Popat MohiteAETs St. John Institute of Pharmacy and Research, Palghar, Maharashtra, 401 404, India. mohitepb@gmail.com.
Sudarshan SinghOffice of Research Administration, Chiang Mai University, Chiang Mai, 50200, Thailand.
Vijay ChidrawarSchool of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS), Deemed-to-University, Green Industrial Park, TSIIC, Polepally, Jadcherla, Hyderabad, Telangana, 509301, India. vijay.chidrawar@nmims.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence indicates that chloride channels (ClCs) significantly affect the pathogenesis of inflammatory bowel disease (IBD) through their regulatory roles in mast cell function and epithelial integrity. IBD, encompassing conditions such as Crohn's disease and ulcerative colitis, involves chronic inflammation of the gastrointestinal tract, where channels influence immune responses, fluid balance, and cellular signalling pathways essential for maintaining mucosal homeostasis. This review examines the specific roles of ClC in mast cells, focussing on the regulation of mast cell activation, degranulation, cytokine release, and immune cell recruitment in inflamed tissues. Key channels, including Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and ClC-2, are discussed in detail because of their involvement in maintaining intestinal epithelial barrier function, a critical factor disrupted in IBD. For example, CFTR facilitates chloride ion transport across epithelial cells, which is essential for mucosal hydration and maintenance of the intestinal barrier. Reduced CFTR function can compromise this barrier, permitting microbial antigens to penetrate the underlying tissues and triggering excessive immune responses. ClC-2, another chloride channel expressed in mast cells and epithelial cells, supports tight junction integrity, contributes to barrier function, and reduces intestinal permeability. Dysregulation of these channels is linked to altered mast cell activity and excessive release of pro-inflammatory mediators, exacerbating IBD symptoms, such as diarrhoea, abdominal pain, and tissue damage. Here, we review recent pharmacological strategies targeting ClC, including CFTR potentiators and ClC-2 activators, which show the potential to mitigate inflammatory responses. Additionally, experimental approaches for selective modulation of chloride channels in mast cells have been explored. Although targeting ClC offers promising therapeutic avenues, challenges remain in achieving specificity and minimizing side effects. This review highlights the therapeutic potential of Cl channel modulation in mast cells as a novel approach for IBD treatment, aiming to reduce inflammation and restore intestinal homeostasis in affected patients.

Indexed as

Chloride ChannelsCystic Fibrosis Transmembrane Conductance RegulatorInflammatory Bowel DiseasesMast CellsAnimalsHumansIntestinal MucosaChloride ChannelsCystic Fibrosis Transmembrane Conductance RegulatorChloride channelCystic fibrosis transmembrane conductance regulatorDrug targetsInflammatory bowel diseaseIon channelsMast cells

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.